HealthDay News — For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8mg is efficacious and tolerable, according to a study ...

The Food and Drug Administration (FDA) has approved Iluvien® (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious ...

Daridorexant, a dual orexin receptor antagonist, is currently approved for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

First Xolair biosimilar approved; wearable furosemide delivery system gains expanded indication; implant approved for macular telangiectasia; novel treatment shows promise in hypertension; and testing ...

The recommendations were made following a meeting that included experts from the FDA, the Centers for Disease Control and Prevention, and the Department of Defense.

Hormone therapy has indirect effect on cognitive decline through regional tau accumulation; no links with tau for women younger than 70 years ...

HealthDay News — Although most manufacturer reports of medical device adverse events are reported on time, a considerable proportion are submitted late, according to a study published online March 12 ...

HealthDay News — Short sleep (<7.7 hours) among adolescents is associated with elevated blood pressure (systolic ≥120mmHg and diastolic <80mmHg), according to a study presented at the American Heart ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

Topline data were announced from a phase 2/3 trial evaluating Flebogamma 5% DIF (immune globulin intravenous ) in patients with post-polio syndrome (PPS).

Significant association seen for patients referred for asthma/query asthma, but not those referred for other reasons.

HealthDay News — Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss, according to a research letter published online March 5 in JAMA Surgery ...